Jump to content

webtrekker

Members
  • Posts

    1,065
  • Joined

  • Last visited

  • Days Won

    6

Everything posted by webtrekker

  1. *** IMPORTANT NEWS *** https://fudgeys.co.uk/chope.mp4
  2. When the day comes to dangle them all I hope they keep the ringleaders till last, to give them a full sense of the fear and panic they are so fond of.
  3. Another article exposing the vaccine contents. Their final thoughts are interesting... Final Thoughts The NWO controllers must have known people would eventually analyze the contents of the vax under microscopy and discover what was in them. At the start of the scamdemic, it seemed that access to the vials was tightly controlled, but now, many independent doctors are getting their hands on them. Did they really think they would get away with hiding the contents from the public forever? Or do they think their plan is too far advanced for this exposure to matter? Or are they glad for it to come out now, so as to induce a sense of learned helplessness in the masses? The evidence discovered by these doctors and presented here (and in previous articles) could easily be used in a court of law in countless cases relating to the fake COVID pandemic and emergency. Humanity is literally being injected with synthetic substances, some of which self-assemble and may even be self-aware. Transhumanism is not coming; it’s here. https://www.globalresearch.ca/covid-vax-contents-2-more-docs-reveal-findings-microscopy-images/5758000
  4. I've just ordered a huge pile of Stanley Johnson and Dr. Hilary books from Amazon. I mean, with all the shortages occuring daily, you never know when toilet rolls will disappear from the shelves again.
  5. And here's me thinking it was only human shit in the sewers. How did all that bullshit get mixed in with it?
  6. Looks like you're between the Devil and the deep blue sea here mate. The only hope I can give you, and also hope that your eyes don't deteriorate much further in the meantime, is that (from my post above) it looks like PCR tests will be withdrawn over the next 2 to 3 months as they have been accepted by the CDC as useless. Let's hope this happens in your country too.
  7. Strangely enough, the CDC itself said a while back that PCR tests were useless and that they would ditch them ... in December. Why wait until December? Since this is obviously part of the script then expect to see the Tories and governments worldwide scrapping the tests.
  8. There are 27 Categories of Adverse Reactions in the database. Taking just ONE of these Categories, Cardiac Disorders, expands to this .. Cardiac disorders (107441) Palpitations (36366) Tachycardia (25271) Myocarditis (8243) Pericarditis (5984) Arrhythmia (5688) Atrial fibrillation (5423) Myocardial infarction (4012) Angina pectoris (3068) Cardiac arrest (2705) Bradycardia (2201) Acute myocardial infarction (2090) Cardiac failure (2053) Cardiac flutter (1989) Extrasystoles (1650) Cardiovascular disorder (1527) Pericardial effusion (1359) Cardiac disorder (1324) Sinus tachycardia (1065) Cardio-respiratory arrest (1013) Ventricular extrasystoles (1009) Supraventricular tachycardia (692) Cardiac discomfort (602) Cardiac failure congestive (586) Cardiomegaly (512) Acute coronary syndrome (492) Atrial flutter (465) Ventricular tachycardia (382) Cardiac failure acute (346) Ventricular fibrillation (345) Cardiogenic shock (332) Coronary artery disease (294) Cardiomyopathy (280) Supraventricular extrasystoles (278) Postural orthostatic tachycardia syndrome (255) Myocardial ischaemia (239) Atrioventricular block (230) Sinus bradycardia (218) Left ventricular dysfunction (213) Mitral valve incompetence (212) Tachyarrhythmia (204) Intracardiac thrombus (201) Coronary artery thrombosis (196) Coronary artery occlusion (195) Bundle branch block right (193) Atrioventricular block complete (170) Pulseless electrical activity (162) Cardiac fibrillation (160) Stress cardiomyopathy (139) Tricuspid valve incompetence (139) Ventricular hypokinesia (132) Cardiac tamponade (126) Bundle branch block left (120) Sinus arrhythmia (116) Congestive cardiomyopathy (113) Left ventricular failure (111) Left ventricular hypertrophy (108) Arteriosclerosis coronary artery (104) Coronary artery stenosis (101) Atrial tachycardia (99) Angina unstable (98) Cardiopulmonary failure (90) Cardiovascular insufficiency (88) Atrioventricular block second degree (86) Carditis (85) Pleuropericarditis (81) Aortic valve incompetence (78) Arrhythmia supraventricular (77) Cardiac dysfunction (77) Atrioventricular block first degree (73) Tachycardia paroxysmal (73) Right ventricular failure (72) Cardiac failure chronic (69) Cardiac ventricular thrombosis (68) Coronary artery dissection (68) Right ventricular dysfunction (67) Ventricular arrhythmia (63) Hypertensive heart disease (60) Acute left ventricular failure (56) Diastolic dysfunction (56) Heart valve incompetence (54) Myocardial oedema (50) Cardiovascular symptom (49) Myocardial fibrosis (46) Acute cardiac event (44) Pericardial haemorrhage (44) Atrial thrombosis (43) Right ventricular dilatation (43) Mitral valve prolapse (42) Arteriospasm coronary (41) Cardiac valve disease (38) Sinus node dysfunction (37) Cor pulmonale acute (35) Sinus arrest (33) Pericardial fibrosis (32) Ventricular hypertrophy (31) Atrial enlargement (30) Bundle branch block (30) Left atrial enlargement (30) Cor pulmonale (29) Ischaemic cardiomyopathy (29) Systolic dysfunction (29) Chronic left ventricular failure (28) Ventricular dysfunction (28) Aortic valve stenosis (27) Left ventricular dilatation (27) Cardiac hypertrophy (26) Left atrial dilatation (26) Heart alternation (23) Myocardial rupture (22) Tachycardia foetal (21) Conduction disorder (19) Myocardial necrosis (19) Nodal rhythm (19) Right atrial dilatation (19) Right ventricular enlargement (19) Cardiac aneurysm (18) Cardiac asthma (18) Pericarditis constrictive (18) Prinzmetal angina (18) Right ventricular hypertrophy (18) Foetal cardiac arrest (17) Hyperdynamic left ventricle (17) Aortic valve calcification (16) Coronary artery embolism (16) Right atrial enlargement (16) Bradyarrhythmia (15) Pulmonary valve incompetence (14) Supraventricular tachyarrhythmia (14) Left ventricular enlargement (13) Mitral valve calcification (13) Pericardial disease (12) Cardiac sarcoidosis (11) Paroxysmal arrhythmia (11) Bradycardia foetal (10) Cardio-respiratory distress (10) Defect conduction intraventricular (10) Microvascular coronary artery disease (10) Nodal arrhythmia (10) Pericardial rub (10) Ventricular tachyarrhythmia (10) Aortic valve sclerosis (9) Eosinophilic myocarditis (9) Long QT syndrome (9) Coronary artery dilatation (8) Dilatation atrial (8) Dilatation ventricular (8) Torsade de pointes (8) Ventricular enlargement (8) Agonal rhythm (7) Aortic valve disease (7) Autoimmune myocarditis (7) Cardiac perfusion defect (7) Cardiac septal hypertrophy (7) Cardiorenal syndrome (7) Dressler's syndrome (7) Mitral valve stenosis (7) Tachycardia induced cardiomyopathy (7) Wolff-Parkinson-White syndrome (7) Aortic valve thickening (6) Brugada syndrome (6) Cardiac amyloidosis (6) Cardiac ventricular disorder (6) Mitral valve disease (6) Paroxysmal atrioventricular block (6) Sinoatrial block (6) Ventricular failure (6) Arrhythmia neonatal (5) Bifascicular block (5) Bundle branch block bilateral (5) Cardiovascular deconditioning (5) Chordae tendinae rupture (5) Coronary artery aneurysm (5) Hepatojugular reflux (5) Hypertensive cardiomyopathy (5) Immune-mediated myocarditis (5) Interventricular septum rupture (5) Low cardiac output syndrome (5) Myocardial hypoxia (5) Ventricular dyskinesia (5) Cardiomyopathy acute (4) Intracardiac mass (4) Kounis syndrome (4) Mitral valve thickening (4) Rhythm idioventricular (4) Silent myocardial infarction (4) Coronary ostial stenosis (3) Endocarditis noninfective (3) Heart valve stenosis (3) Myocardial depression (3) Pericardial mass (3) Pneumopericardium (3) Pulmonary valve disease (3) Restrictive cardiomyopathy (3) Right ventricular diastolic collapse (3) Ventricle rupture (3) Ventricular dyssynchrony (3) Ventricular flutter (3) Arteritis coronary (2) Atrioventricular node dysfunction (2) Degenerative mitral valve disease (2) Endocardial disease (2) Foetal heart rate deceleration abnormality (2) Foetal heart rate disorder (2) Giant cell myocarditis (2) Heart valve calcification (2) Hypersensitivity myocarditis (2) Myocardial haemorrhage (2) Papillary muscle rupture (2) Pericardial cyst (2) Right ventricular hypertension (2) Sigmoid-shaped ventricular septum (2) Toxic cardiomyopathy (2) Tricuspid valve disease (2) Abnormal precordial movement (1) Accelerated idioventricular rhythm (1) Acute right ventricular failure (1) Adams-Stokes syndrome (1) Anginal equivalent (1) Atrioventricular conduction time shortened (1) Bezold-Jarisch reflex (1) Cardiac arrest neonatal (1) Cardiac steatosis (1) Cardiac valve discolouration (1) Cardiac valve sclerosis (1) Cardiomyopathy alcoholic (1) Cardiomyopathy neonatal (1) Cardiotoxicity (1) Chronic coronary syndrome (1) Foetal arrhythmia (1) Foetal heart rate acceleration abnormality (1) Gastrocardiac syndrome (1) Hypertensive cardiomegaly (1) Intrapericardial thrombosis (1) Ischaemic mitral regurgitation (1) Lupus endocarditis (1) Malignant hypertensive heart disease (1) Myocardial stunning (1) Myocarditis post infection (1) Neonatal tachycardia (1) Obesity cardiomyopathy (1) Parasystole (1) Pulmonary valve stenosis (1) Sinusoidal foetal heart rate pattern (1) Tricuspid valve prolapse (1) Trifascicular block (1) Wandering pacemaker (1) Ventricular hyperkinesia (1) Ventricular remodelling (1)
  9. Just had a look at this, especially the ADR's (Adverse Drug Reactions) for previous years .. FUCKING UNBELIEVABLE!!!
  10. This is exactly the conclusion I am coming to myself. The 'Elites' own all of the Banks that in turn control all of the world's governments. If it's simply money they want then their own banks can pull trillons from thin air. Money is a distraction, that's all.
  11. They call us 'Anti-Vaxxers' and 'Conspiracy Theorists' so I reckon it's time we called them by their true name ...
  12. Anyone watch the 'Goliath' series on Prime? This intro came up in Season 4, very apt! ...
  13. About time too ... SOME REAL WARRIORS OUTSIDE OF DR HILARY JONES’ HOUSE https://www.bitchute.com/video/gAC1XRMFFgt4/
  14. Press release29 June 2021Brussels COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics * “Vaccination against COVID-19 offers the best way to end the pandemic and get back to a normal life. In parallel, we are working to have the best treatments available for those who are infected.” * The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients. Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.” The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are: A new COVID-19 indication for existing medicines: baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency: combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review regdanvimab from Celltrion: under rolling review sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review Next Steps The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants. The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria. The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes. The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year. The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible. Background The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.
  15. Press release29 June 2021Brussels COVID-19 Therapeutics Strategy: Commission identifies five promising candidate therapeutics * “Vaccination against COVID-19 offers the best way to end the pandemic and get back to a normal life. In parallel, we are working to have the best treatments available for those who are infected.” * The EU Strategy on COVID-19 Therapeutics delivers today its first outcome, with the announcement of the first portfolio of five therapeutics that could soon be available to treat patients across the EU. Four of these therapeutics are monoclonal antibodies under rolling review by the European Medicines Agency. Another one is an immunosuppressant, which has a marketing authorisation that could be extended to include the treatment of COVID-19 patients. Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are taking the first step towards a broad portfolio of therapeutics to treat COVID-19. Whilst vaccination is progressing at increasing speed, the virus will not disappear and patients will need safe and effective treatments to reduce the burden of COVID-19. Our goal is clear, we aim to identify more front-runner candidates under development and authorise at least three new therapeutics by the end of the year. This is the European Health Union in action.” The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy. The products are: A new COVID-19 indication for existing medicines: baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency: combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review regdanvimab from Celltrion: under rolling review sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review Next Steps The Commission will draw up a portfolio of at least 10 potential COVID-19 therapeutics by October, building on the work of the newly established expert group on COVID-19 variants. The selection process will be objective and science based, with selection criteria agreed with the Member States. Since different types of products are needed for different patient populations and different stages and severity of the disease, the expert group will identify product categories and select the most promising therapeutics candidates for each category based on science based criteria. The portfolio will contribute to the objective of having at least three new therapeutics authorised by October and possibly two more by the end of the year. The European Medicines Agency will start more rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes. The Commission recently concluded a joint procurement of monoclonal antibodies (casirivimab and imdevimab) and could launch more by the end of the year. The first industry matchmaking event on therapeutics will be organised on the 12-13 July to ensure that once authorised therapeutics are produced in sufficient quantity as soon as possible. Background The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. The Strategy, which focuses on the treatment of patients with COVID-19, works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.
  16. HEADS UP - The reason behind the booster shots - IMPORTANT NEW INFO! This is well worth listening to ... [CLICK IMAGE FOR VIDEO]
  17. Saw this in a comment on the net ... GO (Graphene Oxide) is made of Carbon, 6 neutrons, 6 electrons and 6 protons. 6uild 6ack 6etter folks.
×
×
  • Create New...